Literature DB >> 8371360

Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.

P Sova1, D J Volsky.   

Abstract

The rate-limiting steps in infection by human immunodeficiency virus type 1 (HIV-1) deficient in the viral infectivity factor, Vif, are unknown. As a measurement of completion of the early stages of the HIV-1 life cycle, the levels of viral DNA were examined by polymerase chain reaction amplification during infection by vif-positive and vif-negative viruses of MT-2 and H9 cells, in which vif is required for HIV-1 replication. Viral DNA was detected within hours of infection by both viruses, but the accumulation of vif-negative virus DNA was impeded in terms of both extent and kinetics. Inefficient viral DNA synthesis correlated with restricted replication of the vif-negative virus. Increasing the input dose of vif-negative virus increased viral DNA levels within 24 h of infection but failed to overcome the block to subsequent DNA synthesis and productive infection. Infection of C8166 cells, in which vif function is dispensable, resulted in efficient DNA synthesis by vif-positive and vif-negative viruses. We conclude that one defect in the replication of vif-negative HIV-1 in nonpermissive cells occurs prior to or during viral DNA synthesis and may reflect processes required for efficient nucleocapsid internalization or activation of reverse transcription.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8371360      PMCID: PMC238061     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Kinetics of early HIV-1 gene expression in infected H9 cells assessed by PCR.

Authors:  I K Hewlett; S J Geyer; C A Hawthorne; M Ruta; J S Epstein
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

2.  Development of techniques to analyse the formation of HIV provirus in primary human macrophages.

Authors:  M Collin; W James; S Gordon
Journal:  Res Virol       Date:  1991 Mar-Jun

3.  Prevalence of antibodies to recombinant virion infectivity factor in the sera of prospectively studied patients with HIV-1 infection.

Authors:  S Schwander; R W Braun; J E Kühn; F T Hufert; P Kern; M Dietrich; U Wieland
Journal:  J Med Virol       Date:  1992-02       Impact factor: 2.327

4.  Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells.

Authors:  H Akari; J Sakuragi; Y Takebe; K Tomonaga; M Kawamura; M Fukasawa; T Miura; T Shinjo; M Hayami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity.

Authors:  K Sakai; X Y Ma; I Gordienko; D J Volsky
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses.

Authors:  M Kishi; Y Nishino; M Sumiya; K Ohki; T Kimura; T Goto; M Nakai; M Kakinuma; K Ikuta
Journal:  J Gen Virol       Date:  1992-01       Impact factor: 3.891

7.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Conservation of amino-acid sequence motifs in lentivirus Vif proteins.

Authors:  M S Oberste; M A Gonda
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

9.  Human immunodeficiency virus type 1 vif, vpr, and vpu mutants can produce persistently infected cells.

Authors:  Y Nishino; M Kishi; M Sumiya; K Ogawa; A Adachi; K Maotani-Imai; S Kato; K Hirai; K Ikuta
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

10.  Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  Virology       Date:  1991-08       Impact factor: 3.616

View more
  90 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

5.  HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition.

Authors:  Jiangfang Wang; Emma L Reuschel; Jason M Shackelford; Lauren Jeang; Debra K Shivers; J Alan Diehl; Xiao-Fang Yu; Terri H Finkel
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

6.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

8.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

9.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.